Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Markman

Showing results (11-20 of 545) with videos related to

Pageof 55
Sort By:
Journal of Cancer Research and Clinical Oncology|January 1, 1993
The use of serum tumor markers in the management of patients with malignancyM Markman
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1996
Supportive careM Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1996
Carboplatin and cisplatin: are they equivalent in efficacy in "optimal residual" advanced ovarian cancer?M Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1996
Paclitaxel in the management of ovarian cancer: what we know and what we have yet to learnM Markman
Cleveland Clinic Journal of Medicine|September 1, 1996
What does tumor shrinkage mean to the patient receiving chemotherapy?M Markman
Cleveland Clinic Journal of Medicine|May 1, 1997
Ethical issues in clinical trials in oncologyM Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1996
Clinical practice guidelines in oncology: pros and consM Markman
Annals of Medicine|August 1, 1996
Intraperitoneal chemotherapy in the treatment of ovarian cancerM Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1994
Thirty-fifth annual meeting of the American Society of Hematology, St. Louis, Missouri, December 1993M Markman
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1992
Supportive careM Markman
Pageof 55

Showing results (11-20 of 545) with videos related to

Sort By:
Pageof 55
Journal of Cancer Research and Clinical Oncology|January 1, 1993
The use of serum tumor markers in the management of patients with malignancyM Markman
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1996
Supportive careM Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1996
Carboplatin and cisplatin: are they equivalent in efficacy in "optimal residual" advanced ovarian cancer?M Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1996
Paclitaxel in the management of ovarian cancer: what we know and what we have yet to learnM Markman
Cleveland Clinic Journal of Medicine|September 1, 1996
What does tumor shrinkage mean to the patient receiving chemotherapy?M Markman
Cleveland Clinic Journal of Medicine|May 1, 1997
Ethical issues in clinical trials in oncologyM Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1996
Clinical practice guidelines in oncology: pros and consM Markman
Annals of Medicine|August 1, 1996
Intraperitoneal chemotherapy in the treatment of ovarian cancerM Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1994
Thirty-fifth annual meeting of the American Society of Hematology, St. Louis, Missouri, December 1993M Markman
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1992
Supportive careM Markman
Pageof 55